For an extended period, Edward (Ed) Waldner experienced a pervasive sense of fatigue, a persistent drain on his energy levels irrespective of his daily activities. This unexplained exhaustion led him to consider possibilities such as sleep apnea, while also noticing subtle alterations in his gait, specifically a tendency for his heels to drag. These physical changes, initially dismissed as minor, eventually prompted him to seek medical attention when they escalated significantly one particular day, leading him to an emergency department.
Upon examination, medical professionals identified a mass within his brain, necessitating an immediate consultation with an oncologist. Subsequent diagnosis revealed the presence of glioblastoma, a particularly virulent and frequently fatal form of brain cancer. The established therapeutic regimen for this condition typically involves surgical intervention to excise as much of the tumor as medically feasible, followed by a course of radiation therapy and chemotherapy. Despite the rigorous application of these standard treatments, glioblastoma is notoriously prone to recurrence, presenting a formidable challenge in achieving long-term remission.
In an effort to enhance treatment outcomes for glioblastoma, researchers at the University of Calgary are investigating the potential efficacy of high-dosage vitamin B3, also recognized as niacin, when administered in conjunction with conventional therapeutic modalities. Mr. Waldner was invited to participate in a clinical trial designed to explore this very avenue. He expressed a willingness to contribute to research, stating, "I have no problem trying to help anybody. I agreed. I want to help myself too." He further elaborated on the psychological benefits of participating, noting, "I can tell you being part of this research helps me mentally because we’re trying. When I left the hospital after surgery I was told, that’s it, that’s all we can do."
This pioneering research initiative is spearheaded by Dr. Gloria Roldan Urgoiti, an accomplished neuro-oncologist, and Dr. Wee Yong, a distinguished neuroscientist whose work delves into the intricate interplay between the immune system and the brain. Both physicians are affiliated with esteemed institutions such as the Hotchkiss Brain Institute and the Arnie Charbonneau Cancer Institute. Their collaborative research program is fundamentally aimed at discerning whether niacin can effectively revitalize compromised immune cells, thereby empowering them to mount a more effective assault against tumor cells. The foundational stages of this project commenced in Dr. Yong’s laboratory, utilizing murine models. Initial experimental results demonstrated a statistically significant extension of survival rates in the treated mice, a finding that provided the impetus for the team to advance to a Phase I and II clinical trial involving human participants.
The underlying scientific premise of this research posits that while the human immune system is inherently designed to combat and inhibit tumor development, glioblastoma possesses a remarkable capacity to suppress these crucial immune responses. Dr. Yong, a professor at the Cumming School of Medicine (CSM), elaborates on this phenomenon: "Normally the immune system will try to counter and prevent tumor growth, however, this brain cancer suppresses the immune system." He further explains the proposed mechanism of niacin’s action: "Niacin treatment rejuvenates immune cells so they can do what they are supposed to do, attack and kill the cancer cells. I see it as an ongoing ‘battle for the brain’." This conceptualization highlights the dynamic and challenging nature of confronting such an aggressive malignancy.
The clinical trial was meticulously designed with dual objectives: to ascertain the maximum tolerable dosage of controlled-release niacin that can be safely administered, and to evaluate its potential therapeutic benefits when integrated with standard chemotherapy and radiotherapy protocols. Prior to the study’s commencement, researchers established a critical benchmark for success. The trial was slated for termination if progression-free survival at the six-month mark did not exhibit an improvement of at least 20 percent when compared to outcomes documented in previous, similar studies.
Remarkably, early findings derived from an initial cohort of 24 patients have surpassed this predetermined target. At the conclusion of the six-month assessment period, an impressive 82 percent of participants demonstrated no discernible signs of disease progression. This figure represents a substantial 28 percent enhancement in progression-free survival relative to historical data from prior glioblastoma treatment studies. The researchers view these preliminary results as profoundly encouraging, particularly given the persistent lack of a cure for this devastating cancer.
Dr. Roldan Urgoiti, a clinical associate professor at the CSM, underscores the severity of glioblastoma: "Glioblastoma is the most aggressive brain cancer in adults. Survival of patients with this condition hasn’t changed significantly for 20-years." She emphasizes the critical need for exploring novel therapeutic avenues, while simultaneously stressing the paramount importance of rigorous oversight: "Anything that may help should be explored but it requires strict protocols and safety monitoring."
The compelling findings from this research have been formally disseminated through publication in the esteemed Journal of Neuro-Oncology, providing a platform for the scientific community to review and build upon these discoveries. It is imperative for researchers to strongly caution that the administration of high doses of any vitamin, including niacin, carries inherent risks and can potentially lead to adverse health consequences if not meticulously supervised by qualified medical professionals. The ongoing study is continuing its enrollment process, with the research team anticipating the completion of their final comprehensive analysis following the recruitment of 48 participants. This milestone is projected to occur by the end of 2026 or in the early months of 2027.
Regarding Mr. Waldner’s personal journey, he reports feeling remarkably well in his current health status. During his routine follow-up imaging scans, he finds solace and gratitude in the consistent feedback from his medical team, which frequently conveys a single, reassuring word: "stable." This research endeavor has been generously supported by grants from the Canadian Institutes of Health Research and the Alberta Cancer Foundation, underscoring the national and provincial commitment to advancing cancer research.
About the Author
